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Background: There is an increasing body of evidence strongly suggesting that glaucoma 
medications may contribute to ocular surface disease and development of dry eye.
Objective: To identify glaucoma patients with dry eye, using a nationally representative sample, 
and to compare clinical and treatment characteristics with controls without dry eye.
Methods: Patients taking intraocular pressure-lowering medications were identified from the 
Medical Expenditure Panel Survey. A matched cohort without glaucoma served as controls. 
Dry eye was identified by diagnosis or use of prescription or over-the-counter medications. 
Demographic and clinical characteristics and medication use patterns were compared.
Results: The analysis identified 629 respondents with glaucoma and 6,934 controls without 
glaucoma. Dry eye was more common among glaucoma respondents than nonglaucoma controls 
(16.5% vs 5.6%, P  0.0001). There was a nonsignificant trend for respondents with dry 
eye to report higher rates of glaucoma adjunctive therapy use compared to those without dry 
eye (44.2% vs 35.0%, P  0.076). Prostaglandin analogs were the most common glaucoma 
medication.
Conclusions: This analysis found that the rate of dry eye was higher in patients with glaucoma 
than in controls. The use of glaucoma adjunctive therapies may increase the rate of dry eye in 
glaucoma patients.
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Introduction
Glaucoma is typically characterized by increased intraocular pressure and progressive 
optic nerve damage. Treatment with intraocular pressure (IOP)-lowering agents can 
be successful at reducing intraocular pressure to target levels, although adjunctive 
therapy is often needed in order to do so.1–3 IOP-lowering agents may contribute to 
ocular surface disease (OSD), in part due to the preservatives used in medications. In 
particular, benzalkonium chloride (BAK), a preservative used in most IOP-lowering 
agents, has been shown in clinical and nonclinical settings to contribute to OSD, with 
greater difficulties associated with increased exposure to BAK through more medica-
tions or longer duration of use.4,5
Although little is known about the reasons for discontinuation or lack of adherence 
with glaucoma treatments, long-term adherence with glaucoma treatments is poor, 
with approximately half of glaucoma patients not continuing on medication past six 
months.6,7 Further, adherence rates may be associated with the type of medication, 
with higher adherence to prostaglandin analogs than beta-blockers.6 Adherence is 
affected by patient beliefs, disease characteristics, and satisfaction with treatment.8 Clinical Ophthalmology 2009:3 646
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One possible reason for discontinuation or inadequate 
adherence with glaucoma treatment is the development of 
OSD resulting in dry eye.4,5
The prevalence of dry eye, known as keratoconjunctivitis 
sicca, is highly variable in the literature.9 This may be driven 
somewhat by the wide range of practical definitions for dry 
eye, which cover symptom intensity and frequency, clinical 
characteristics, and impact.10 Multiple diagnostic tools exist 
and there is some, but not complete, overlap among them.11 
The American Academy of Ophthalmology recognizes dry 
eye as a group of disorders of tear production or evapora-
tion that lead to discomfort or impaired vision and that 
may damage the ocular surface.9 Risk factors for dry eye 
include age, vitamin or hormone intake or deficiencies, and 
medications, including IOP-lowering agents.9 Topical treat-
ments for dry eye include cyclosporine, anti-inflammatory 
agents, mucolytic agents (available by prescription only) 
and over-the-counter lubricants or artificial tears. Treatment 
for dry eye is aimed not only at alleviating symptoms but 
also at preventing structural damage. Among patients with 
glaucoma, the prevalence of dry eye is higher than in the 
general population.12 However, few studies have explored 
the prevalence of concomitant dry eye and glaucoma in a 
general population.
The objective of this study was to use a nationally-
representative sample to identify patients with glaucoma 
with and without dry eye and to evaluate their clinical and 
treatment characteristics.
Methods
The Medical Expenditure Panel Survey (MEPS) is a national 
survey conducted under the auspices of the National Center 
for Health Statistics. Individuals, families, and medical 
providers are interviewed for the Household Component; 
the Insurance Component also includes interviews with 
employers. Each panel consists of five interviews over a two-
year period. Participants are selected from a representative 
sample of the participants in the previous year’s National 
Health Interview Survey. Sampling weights are provided to 
project to the US population. Data collected include, but are 
not limited to personal characteristics, medical encounters 
and diagnoses, medication use, and insurance coverage. 
Providers and pharmacies provide verification of health care 
resource utilization while use of over-the-counter medications 
is self-reported.
For this analysis, three panels, covering the calendar 
years 2003–2006, were examined. Participants with glau-
coma were identified by the use of a glaucoma medication 
(MEPS medication code 164 ‘topical glaucoma agents’). 
A healthy, or nonglaucoma, comparator group was identi-
fied by including respondents whose ages were in the inter-
quartile range (ie, from the 25th to 75th percentile) of the 
glaucoma patients. In each cohort, those with concomitant 
dry eye were identified by a diagnosis code (International 
Statistical Classification of Diseases and Related Health 
Problems [ICD-9] code 375) or the use of a prescription or 
over-the-counter dry eye medication. Dry eye medications 
were initially identified by medication code (MEPS medica-
tion code 168 ‘ophthalmic lubricants and irritations’) with 
the list of medications also manually examined. Procedures 
that could be indicative of either condition, such as trabecu-
loplasty or punctal occlusion, were not specifically reviewed 
and used as tools for identifying patients with glaucoma or 
dry eye; the focus of the study was on medication use and its 
impact rather than a diagnosis of the condition of interest.
Participants were characterized in terms of demographic 
characteristics (age, gender, race, insurance, health status), 
ophthalmic comorbidities (identified by ICD-9 diagnosis 
codes 360–379 and present in 1% or more of respondents 
with glaucoma), and nonophthalmic chronic conditions of 
interest. For participants with glaucoma, glaucoma medica-
tions were described by type (adrenergics, beta blockers, 
carbonic anhydrase inhibitors, miotics, prostaglandin 
analogs, and fixed combinations). The use of monotherapy vs 
adjunctive therapies was also compared, with the use of 
adjunctive therapy defined as the listing of two or more 
glaucoma medications at one or more interviews during the 
follow-up period. Among the cohorts with glaucoma and 
matched controls initially identified, a secondary analysis 
was conducted, comparing patients who had dry eye with 
those who did not. Their characteristics were examined based 
on the presence of glaucoma. MEPS sampling weights were 
used throughout the analysis. The analysis was conducted 
using SAS software (v. 9.2; SAS Institute, Cary, NC), with 
chi-squared tests for categorical variables and analysis of 
variance used for continuous variables.
Results
Across the three panels, a total of 629 respondents were 
identified with glaucoma and the nonglaucoma control group 
included 6,934 respondents. In the cohort with glaucoma, 
16.5% had evidence of dry eye compared to 5.6% in the 
nonglaucoma controls (P  0.0001).
Demographic characteristics of glaucoma and nonglau-
coma control cohorts are presented in Table 1. Gender and 
age are reflective of the known epidemiology of glaucoma. Clinical Ophthalmology 2009:3 647
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Table 1 Patients with glaucoma vs controls: Demographic characteristics
Characteristic Glaucoma patients Controls Total
Without dry eye With dry eye Without dry eye With dry eye Without dry eye With dry eye
n (Respondents) 525 104 6,548 386 7,073 490
Mean Mean Mean Mean* Mean Mean*
Age (years) 66.7 68.2 65.1 67.3 65.2 67.5
Frequency Frequency Frequency Frequency* Frequency Frequency*
Sex, % female 58.7% 58.8% 52.6% 61.8% 53.1% 61.6%
Race
  White 81.5% 72.7% 85.1% 86.2% 84.8% 85.2%
  Black 14.3% 22.1% 9.6% 8.2% 9.9% 9.3%
    Asian 2.2% 2.2% 3.3% 3.6% 3.2% 3.5%
  Multiple races 1.6% 1.0% 1.2% 1.2% 1.2% 1.2%
  Other 0.4% 1.9% 0.9% 0.8% 0.9% 0.9%
Notes: *Indicates significant differences (P  0.05): glaucoma cohort: none. Controls with and without dry eye: age and gender.  Total with and without dry eye: age and 
gender.
Also, a higher percentage of females than males in both 
the glaucoma and nonglaucoma cohorts experienced dry 
eye requiring prescription or over-the-counter medications 
for symptom relief. Table 2 provides detail on clinical 
characteristics. In all groups, a majority of respondents stated 
that they were in ‘very good’ or ‘good’ health. Patients with 
dry eye experienced more visual impairment in both the 
glaucoma and control groups. The most common ophthalmic 
comorbidity was cataract, with macular degeneration also 
not uncommon. As expected, the rate of disorders of the 
lacrimal system was much higher in patients with dry eye 
and it was not reported at all in patients who were not using 
medications for dry eye. The most common nonophthalmic 
chronic conditions were hypertension, hypercholesterolemia 
and diabetes in both the glaucoma and nonglaucoma groups. 
Patients with dry eye had significantly higher rates of hyper-
tension and diabetes.
Medication use is presented in Table 3. Respondents 
could report taking more than one medication; as a result 
the sum of the frequency of medications exceeds 100%. 
Prostaglandin analogs were the most often reported glaucoma 
medication (65% of all glaucoma respondents and 53% of 
respondents with glaucoma and dry eye). Just over one-third 
(36.6%) of patients reported two or more glaucoma medica-
tions at any interview during the panel. There was a trend 
for glaucoma patients with dry eye to report higher rates 
of adjunctive therapy use compared to glaucoma patients 
without dry eye (44.2% vs 35.0%, P  0.076).
Patients with dry eye were also compared by the presence 
of glaucoma. There were a total of 490 dry eye patients, 104 
of whom had glaucoma compared to 525 of 7,073 patients 
without dry eye reporting glaucoma (21.2% vs 7.4%, 
P  0.0001). Demographic characteristics for glaucoma 
and nonglaucoma groups were similar; however, a larger 
percentage of black patients used glaucoma medications in 
all cohorts. For example, among patients with dry eye and 
glaucoma, 22.1% were black, while among dry eye patients 
without glaucoma, only 8.2% were black.
Discussion
This analysis suggests that one in six patients with glaucoma 
have dry eye symptoms severe enough that they seek some 
form of treatment. The rate of dry eye among age-matched 
controls not using IOP-lowering medications was only about 
one-third (5.6%) of the rate for patients with glaucoma 
(16.5%). Similarly, patients with dry eye were also being 
treated for glaucoma significantly more often than those 
without dry eye. Finally, there was a nonsignificant trend for 
higher rates of dry eye among glaucoma patients reporting 
adjunctive therapy use.
A review of the epidemiology of dry eye found published 
prevalence ranging from 6% to 34%.13 In a general population 
aged 43–84 years, one study found that 13% reported dry 
eye symptoms over a five-year period, with higher preva-
lence associated with age and among patients with diabetes 
or allergies.14 Another large study of the general population 
found that the prevalence of dry eye symptoms among men 
ranged from 4%–8%, and was associated with age and the 
presence of hypertension and benign prostatic hyperplasia.15 
Among women, the rate was found to be slightly higher in 
the general population and there were differences by educa-
tional status and geography, with an age-adjusted prevalence Clinical Ophthalmology 2009:3 648
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Table 2 Patients with glaucoma vs controls: Clinical characteristics
Characteristic (n) Glaucoma patients Controls Total
Without dry eye With dry eye Without dry eye With dry eye Without dry eye With dry 
eye
health status
  excellent 2.0% 3.3% 5.8% 2.9% 5.5% 3.0%
    Very good 21.2% 15.9% 25.0% 20.8% 24.7% 20.4%
  good 37.3% 44.0% 38.0% 36.0% 37.9% 36.6%
  Fair 28.0% 22.5% 20.9% 26.3% 21.4% 26.0%
  Poor 8.4% 14.2% 6.7% 11.8% 6.8% 12.0%
  Other (don’t know, not applicable) 3.1% 0.1% 3.6% 2.3% 3.6% 2.1%
Vision impairment
  no impairment 72.5% 67.3%* 85.8% 73.3%* 84.8% 72.9%*
  Some difficulty 16.7% 20.2% 9.5% 19.2% 10.0% 19.3%
  impaired near but not far 7.5% 5.9% 2.3% 5.5% 2.7% 5.5%
  impaired both near and far 1.6% 2.7% 0.3% 1.1% 0.4% 1.2%
  Blind 1.3% 4.0% 0.8% 0.9% 0.9% 1.1%
    Difficulty seeing with contacts/glasses, 
% yes
11.9% 13.1% 3.5% 8.6%* 4.1% 8.9%*
Presence of eye conditions  
(iCD-9 code)
  Disorders of the globe (360) 1.2% 7.2% 1.4% 10.5%* 1.4% 10.3%*
  Other retinal disorders (362) 5.9% 8.1% 2.0% 3.8% 2.2% 4.2%*
  Cataract (366) 13.8% 39.5% 6.5% 45.5%* 7.0% 45.1%*
    Disorders of refraction/accommodation 
(367)
2.0% 2.0% 3.4% 1.6%* 3.3% 1.6%*
    Visual disturbances (368) 1.2% 2.1% 1.3% 5.5% 1.3% 5.2%*
  Blindness and low vision (369) 1.3% 0.8% 0.7% 1.4% 0.8% 1.3%
  Inflammation of eyelids (373) 0.3% 1.5% 0.3% 0.8% 0.3% 0.8%
  Disorders of lacrimal system (375) 0.0% 15.8% 0.0% 20.7% 0.0% 20.5%
  Disorders of optic nerve (377) 0.4% 1.1% 0.1% 0.2% 0.1% 0.3%
  Other disorders of eye (379) 5.0% 10.6% 2.5% 10.4%* 2.7% 10.4%*
Presence of other chronic conditions
  hypertension (401) 47.9% 58.0% 47.2% 54.3%* 47.3% 54.6%*
  hypercholesterolemia (272) 26.6% 34.4% 33.6% 36.9% 33.0% 36.7%
  Diabetes (250) 20.3% 27.7% 17.0% 25.0%* 17.3% 25.2%*
Notes: *Indicates significant differences (P  0.05): Glaucoma cohort: cataract. Controls with and without dry eye: vision impairment, difficulty seeing with contacts/glasses, 
disorders of the globe, cataract, disorders of refraction/accommodation, other disorders of the eye, hypertension, and diabetes.   Total with and without dry eye: vision impair-
ment, difficulty seeing with contacts/glasses, disorders of the globe, other retinal disorders, cataract, disorders of refraction/accommodation, visual disturbances, other disorders 
of the eye, hypertension, and diabetes.
Abbreviation: ICD-9, International Statistical Classification of Diseases and Related Health Problems.
of 7.8%.16 Among the glaucoma patients in our study, 
16.2% of men and 16.8% of women had concomitant dry 
eye, which we deemed not remarkable enough for detailed 
analysis, though it may suggest that the addition of BAK is 
an equilibrating factor that eliminates the difference between 
the sexes. In the much larger control group, though, women 
had a significantly higher rate of dry eye symptoms requiring 
therapy. A clinical study that identified OSD using the Ocular 
Surface Disease Index (OSDI) found that more than half of 
glaucoma patients have at least one symptom, and that the 
use of antiglaucoma agents containing BAK increases the risk 
of OSD.5 A recent study found that the use of multiple IOP-
lowering agents is associated with a significantly increased 
rate of moderate and severe dry eye.17
The rate of concomitant dry eye in this study among 
glaucoma patients, 16.5%, is consistent with existing Clinical Ophthalmology 2009:3 649
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literature, given that the identification methods required a 
respondent be sufficiently symptomatic to seek treatment. 
There is no definitive diagnostic tool for dry eye.13 The 
OSDI may identify subclinical dry eye cases, thus resulting 
in a higher rate compared to that reported here. Alterna-
tively, a study that identifies dry eye only by prescription 
medication and/or an ICD-9 diagnosis might underreport 
cases of dry eye compared to this analysis. Either might lead 
to different outcomes. For example, limiting an analysis to 
prescription medication only would likely capture only the 
most severe cases while using a comprehensive tool such 
as the OSDI might label patients as having dry eye even 
though they had never been sufficiently bothered to seek 
treatment. A database with clinical information as well as 
over-the-counter and prescription data would be required 
in order to evaluate the impact of different case finding 
methods more fully.
The design of this survey made it difficult to ascertain 
if respondents with glaucoma had pre-existing dry eye that 
was exacerbated by topical IOP-lowering therapy or if it 
developed after the start of treatment with IOP-lowering 
agents. Also, there may have been other factors contribut-
ing to dry eye but they could not be fully explored. While 
there was a list of all medications taken by respondents with 
glaucoma, it was not considered feasible to review the list 
for evidence of medications that may be associated with dry 
eye. For example, as oral beta blockers used to treat hyper-
tension can also contribute to dry eye disease, it is possible 
that hypertension treatment could exacerbate any propensity 
towards dry eye from antiglaucoma agents. It would have 
been interesting to know about type of glaucoma and other 
ophthalmic conditions, but the MEPS data include only a 
three-digit ICD-9 code.
We considered identifying patients by glaucoma 
diagnosis rather than only by medication use. However that 
would have presented a challenge, with two very different 
types of patients included using that definition. First, it was 
possible that a single diagnosis could have been recorded 
as part of an evaluation to rule out disease. These patients 
would have had no exposure to glaucoma medications. In 
contrast, it is also possible that we could have identified 
patients with previous surgical interventions whose glau-
coma was monitored but controlled without medications. 
Unless the intervention occurred during the time of obser-
vation, there would be no way to distinguish these patients. 
Patients who did not require medication, either because they 
did not have glaucoma or they were successfully treated 
with a surgical intervention, were not the target group for 
this analysis. Thus, patients identified by diagnosis with no 
evidence of IOP-lowering medication were not included in 
the glaucoma cohort.
In examining the use of adjunctive therapies, we explored 
alternate definitions. Only 33 of the glaucoma patients 
reported two or more antiglaucoma medications at all five 
of the survey interviews, so that definition was deemed too 
restrictive. In fact, 350 of the 629 glaucoma patients only 
mentioned one antiglaucoma medication during the entire 
study period. Other studies have found the rate of adjunctive 
therapy over one year to be less than 30%, at least among 
users of prostaglandin analogs,18,19 so this was not considered 
unusual. Given the low frequency of prescriptions for adjunc-
tive therapy even among those who did report one or more, 
we wonder whether limiting our analysis to patients who 
reported multiple prescriptions would have demonstrated a 
greater differential in dry eye rates compared those with no 
prescriptions. With so few respondents reporting multiple 
adjunctive therapies, though, the analysis would not have had 
sufficient power to detect a significant difference. Also, we 
were unable to separate out adjunctive therapies containing 
BAK that might be more likely to cause dry eye from those 
that do not. At the time of data collection, only one beta 
blocker formulation and one prostaglandin analog were 
available without BAK. However, as the MEPS prescription 
data did not consistently provide brand names, it was not 
possible to make this distinction. Our findings indicated a 
nonsignificant statistical trend for higher rates of dry eye 
among patients reporting use of adjunctive therapies. Had 
the population size been 6% larger with similar rates of dry 
eye, the difference would have been significant; an updated 
analysis using another panel of MEPS data might find that 
the trend reaches significance.
Table 3 Medication use
Medication Glaucoma patients
Without dry eye With dry eye
Frequency^ Frequency^
iOP-lowering agents
  Prostaglandin analogs 64.9% 53.4%
  Beta blockers 36.9% 50.7%
    Adrenergics 20.8% 28.5%
  Combination products 16.7% 19.4%
    Carbonic anhydrase 
inhibitors
11.0% 14.8%
  Miotics 2.0% 2.5%
Notes: ^Total exceeds 100% as patients could report more than one agent.
Abbreviation: iOP, intraocular pressure.Clinical Ophthalmology 2009:3
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The MEPS data are unequaled in terms of scope 
and validity. The survey excludes the military and the 
institutionalized populations but is otherwise nationally rep-
resentative. Diagnoses and resource use are confirmed with 
health care providers and prescription data are validated at 
pharmacies. The inclusion of self-reported over-the-counter 
medications, although not validated, is a valuable addition 
compared with other databases. Self-report can be limited by 
recall bias, which raises analytic challenges,20 though little 
is known about report of over-the-counter medications and 
the extent of recall bias.
The objective of this analysis was to explore the relation-
ship between glaucoma, dry eye, and the use of antiglaucoma 
medications. While further analysis and large epidemio-
logic studies will be useful, these findings demonstrate that 
glaucoma and/or the use of IOP-lowering medications are 
associated with the presence of dry eye. Analysis of addi-
tional panels of MEPS data or other databases that include 
over-the-counter medications would be helpful to confirm 
these findings.
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